InvestorsHub Logo
Followers 22
Posts 1905
Boards Moderated 0
Alias Born 03/22/2021

Re: Galzus Research post# 763487

Wednesday, 04/23/2025 8:59:32 PM

Wednesday, April 23, 2025 8:59:32 PM

Post# of 775775
Also,
"Risk - Uncertain market size for the approved label
Glioblastoma affects well over 200,000 people a year around the world, and it's recognized as a major area of unmet need. However, it's important to keep in mind that the first approval (and the only one submitted by NWBO to date) is restricted to the United Kingdom, where that number is more like 3200 patients per year."

So you don't believe patients will want to travel to UK for life saving safe treatment?

"Not all of these patients will be amenable to surgery, which is necessary to acquire the tissue needed to pulse the patient's dendritic cells with tumor lysate."

Are you serious? Instead they would prefer to be bombarded with chemo and toxic chemicals and have a less chance for survival.?
Did you inquire about the number of patients who are still living years after the treatment?
Did you mention the number of patients who received the treatment with compassionate care? Or survival rates?
A really poor hack job in my opinion that does not credit the good work they've allready done and how they are so close to approval.
Did you even interview one long term survivor of the treatment because guess what, there are a number?
Yes sir, sell now, great advice
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News